Author  
Place of duty  
Title   다발성골수종에 대한 복합화학요법의 치료효과 ( Combination Chemotherapy for the Treatment of Multiple Myeloma )
Publicationinfo   1992 Jan; 024(04): 577-586.
Key_word   Multiple myeloma, Combination chemotherapy
Full-Text  
Abstract   The author compared retrospectively two regimens, VMCBP regimen and VMP regimen for patients with multiple myeloma. Between Jan. 1979 and June 1984, 20 patients were treated with vincristine, melphalan, cyclophosphamide, BCNU, prednisone(VMCBP regimen), and between Jan. 1987 and May 1989, 26 patients were treated with vincristine, melphalan, prednisone(VMP regimen). VMCBP regimen consist of vincristine 0.03 mg/kg IV, day 1; melphalan 0.15 mg/kg PO, day 1-7; cyclophosphamide 10 mg/kg IV, day 1; BCNU 0.5 mg/kg IV, day 1; prednisone 1 mg/kg PO, day 1-7. And, VMP regimen consist of vincristine 0.03 mg/kg IV, day 1; melphalan 0.15 mg/kg PO, day l-7; prednisone 1 mg/kg PO, day 1-7. Courses were repeated every 4 weeks. Treatment was con- tinued until disease progression. In 20 patients with VMCBP regimen, the response rate was 40%(8/20). In 26 patients with VMP regimen, the response rate was 69%(l8/26). There was statistically significant difference (P<0.05) in response rate between two groups. Median duration of response was 18 months in VMCBP group, and 11 months in VMP group. One year survival rate was 79% in VMCBP group, and 80% in VMP group. There was no statistically significant difference in remission duration and survival rate between two groups. Both regimen showed statistically significant survival difference between responders and nonresponders(p<0.01). In summary, VMP regimen showed better response rate than VMCBP regimen. But there was no statstically signifi cant difference in remission duration and survival rate between two groups. Randomized prospective phase III study will be tried.
저 자   김효진(Hyo Jin Kim),서창인(Chang In Suh),박근칠(Keun Chil Park),,김홍태(Heung Tae Kim),허대석(Dae Seog Heo),방영주(Yung Jue Bang),박선양(Seon Yang Park),김병국(Byoung Kook Kim),김노경(Noe Kyeong Kim)